ArticleScientific reports2025
Marine-derived peptides from Rapana venosa inhibit breast cancer cell growth through synergistic mechanisms with doxorubicin.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic potential of crude protein extracts from two Egyptian freshwater snails Lanistes carinatus and Bellamya unicolor.Scientific reports · 2026Article
- Identification, Screening and Mechanism Analysis of Anti-Parkinson's Disease Peptides fromMarine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Marine natural products are a promising source of novel anticancer agents. This study evaluated the antitumor activity of peptide fractions derived from the marine gastropod Rapana venosa against human breast cancer cell lines MCF-7 (estrogen receptor-positive) and MDA-MB-231 (triple-negative). Peptides were isolated by enzymatic hydrolysis and Fast Protein Liquid Chromatography. All seven isolated fractions were systematically screened against four human cancer cell lines (MCF-7, MDA-MB-231, CaCo-2, and HepG2) to assess cancer type selectivity. Cytotoxicity was assessed using MTT assay, while cell cycle progression and apoptosis were analyzed by flow cytometry. Gene expression changes were examined by RT-qPCR. Two peptide fractions, RV1 and RV2, demonstrated remarkable selectivity for breast cancer cells, exhibiting 25-95-fold higher potency compared to other cancer types. These fractions showed significant dose-dependent cytotoxicity with IC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.